LENZ Therapeutics, Inc. (Nasdaq: LENZ) announced its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a successful launch of its product VIZZ® (aceclidine ophthalmic solution) 1.44%. The company reported net product revenues of approximately $1.6 million in the first quarter following the product's launch in October 2025. This revenue was driven by over 20,000 filled prescriptions, with expectations to exceed 45,000 paid prescriptions by the end of the first quarter of 2026. The management expressed confidence in the product's performance, citing broad prescriber uptake and encouraging refill trends. The company plans to expand its sales force from 88 to 117 territories to enhance engagement with eye care professionals (ECPs). Additionally, LENZ submitted a Marketing Authorization Application to the European Medicines Agency for VIZZ, marking its fifth regulatory filing outside the U.S. The company ended the year with a strong cash position of $292.3 million, which is expected to support operations through to positive operating cash flow post-launch.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.